Durvalumab vs Hepatitis B Virus Hbsag Surface Protein Antigen

## Durvalumab vs Hepatitis B Virus Hbsag Surface Protein Antigen: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Hepatitis B Virus Hbsag Surface Protein Antigen**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Hepatitis B Virus Hbsag Surface Protein Antigen — N/A.

## Chemical Properties

**Type**: Durvalumab — Antibody; Hepatitis B Virus Hbsag Surface Protein Antigen — Vaccine component.